

Farhad Jadidi-Niaragh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4617853/publications.pdf>

Version: 2024-02-01

187
papers

7,627
citations

53939

47
h-index

97045

71
g-index

195
all docs

195
docs citations

195
times ranked

11352
citing authors

#	ARTICLE	IF	CITATIONS
1	The Role of the IL-33/ST2 Immune Pathway in Autoimmunity: New Insights and Perspectives. Immunological Investigations, 2022, 51, 1060-1086.	1.0	8
2	TIGIT and CD155 as Immune-Modulator Receptor and Ligand on CD4 ⁺ T cells in Preeclampsia Patients. Immunological Investigations, 2022, 51, 1023-1038.	1.0	15
3	Simultaneous silencing of the A2aR and PD-1 immune checkpoints by siRNA-loaded nanoparticles enhances the immunotherapeutic potential of dendritic cell vaccine in tumor experimental models. Life Sciences, 2022, 288, 120166.	2.0	10
4	The effects of PBMCs-derived exosomes of ankylosing spondylitis patients on T cell profiles. Gene Reports, 2022, 26, 101446.	0.4	5
5	Does CCL19 act as a double-edged sword in cancer development?. Clinical and Experimental Immunology, 2022, 207, 164-175.	1.1	28
6	The role of Th17 cells in the pathogenesis and treatment of breast cancer. Cancer Cell International, 2022, 22, 108.	1.8	25
7	Early stage evaluation of colon cancer using tungsten disulfide quantum dots and bacteriophage nano-biocomposite as an efficient electrochemical platform. Cancer Nanotechnology, 2022, 13, .	1.9	10
8	Xanthohumol: An underestimated, while potent and promising chemotherapeutic agent in cancer treatment. Progress in Biophysics and Molecular Biology, 2022, 172, 3-14.	1.4	12
9	NK cells - Dr. Jekyll and Mr. Hyde in autoimmune rheumatic diseases. International Immunopharmacology, 2022, 107, 108682.	1.7	6
10	Combined inhibition of CD73 and ZEB1 by Arg-Gly-Asp (RGD)-targeted nanoparticles inhibits tumor growth. Colloids and Surfaces B: Biointerfaces, 2021, 197, 111421.	2.5	18
11	Codelivery of STAT3 and PD-L1 siRNA by hyaluronate-TAT trimethyl/thiolated chitosan nanoparticles suppresses cancer progression in tumor-bearing mice. Life Sciences, 2021, 266, 118847.	2.0	43
12	Inhibition of HIF-1 α /EP4 axis by hyaluronate-trimethyl chitosan-SPION nanoparticles markedly suppresses the growth and development of cancer cells. International Journal of Biological Macromolecules, 2021, 167, 1006-1019.	3.6	32
13	Oncostatin M: A mysterious cytokine in cancers. International Immunopharmacology, 2021, 90, 107158.	1.7	35
14	Tumor-associated neutrophils as new players in immunosuppressive process of the tumor microenvironment in breast cancer. Life Sciences, 2021, 264, 118699.	2.0	50
15	Th17 and Treg cells function in SARS-CoV2 patients compared with healthy controls. Journal of Cellular Physiology, 2021, 236, 2829-2839.	2.0	135
16	Angiotensin-converting enzyme as a new immunologic target for the new SARS-CoV α 2. Immunology and Cell Biology, 2021, 99, 192-205.	1.0	5
17	Association of the genetic variants in the <i>endoplasmic reticulum aminopeptidase 2</i> gene with ankylosing spondylitis susceptibility. International Journal of Rheumatic Diseases, 2021, 24, 567-581.	0.9	1
18	The importance of co-delivery of nanoparticle-siRNA and anticancer agents in cancer therapy. Chemical Biology and Drug Design, 2021, 97, 997-1015.	1.5	14

#	ARTICLE	IF	CITATIONS
19	The role of exosomal non-coding RNAs in aging-related diseases. <i>BioFactors</i> , 2021, 47, 292-310.	2.6	12
20	The effects of oxygen-ozone therapy on regulatory T cell responses in multiple sclerosis patients. <i>Cell Biology International</i> , 2021, 45, 1498-1509.	1.4	23
21	T cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer. <i>IUBMB Life</i> , 2021, 73, 726-738.	1.5	23
22	Clinical, Immunologic and Molecular Spectrum of Patients with Immunodeficiency, Centromeric Instability, and Facial Anomalies (ICF) Syndrome: A Systematic Review. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2021, 21, 664-672.	0.6	10
23	Application of newly developed SARS-CoV2 serology test along with real-time PCR for early detection in health care workers and on-time plasma donation. <i>Gene Reports</i> , 2021, 23, 101140.	0.4	13
24	A new approach to the preeclampsia puzzle; MicroRNA-326 in CD4+ lymphocytes might be as a potential suspect. <i>Journal of Reproductive Immunology</i> , 2021, 145, 103317.	0.8	13
25	Blockade of HIF-1 α and STAT3 by hyaluronate-conjugated TAT-chitosan-SPION nanoparticles loaded with siRNA molecules prevents tumor growth. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2021, 34, 102373.	1.7	19
26	Silencing STAT3 enhances sensitivity of cancer cells to doxorubicin and inhibits tumor progression. <i>Life Sciences</i> , 2021, 275, 119369.	2.0	22
27	Simultaneous inhibition of CD73 and IL-6 molecules by siRNA-loaded nanoparticles prevents the growth and spread of cancer. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2021, 34, 102384.	1.7	7
28	Ruxolitinib attenuates experimental autoimmune encephalomyelitis (EAE) development as animal models of multiple sclerosis (MS). <i>Life Sciences</i> , 2021, 276, 119395.	2.0	20
29	Nanocurcumin improves Treg cell responses in patients with mild and severe SARS-CoV2. <i>Life Sciences</i> , 2021, 276, 119437.	2.0	46
30	Chemical composition and cytotoxic activity of the essential oil from the aerial parts of <i>Dorema aucheri</i> . <i>Journal of HerbMed Pharmacology</i> , 2021, 10, 344-350.	0.4	1
31	Different T cell related immunological profiles in COVID-19 patients compared to healthy controls. <i>International Immunopharmacology</i> , 2021, 97, 107828.	1.7	21
32	MicroRNAs Implications in the Onset, Diagnosis, and Prognosis of Osteosarcoma. <i>Current Molecular Medicine</i> , 2021, 21, 573-588.	0.6	6
33	PD-1 blockade: Prospectives for immunotherapy in cancer and autoimmunity. <i>IUBMB Life</i> , 2021, 73, 1293-1306.	1.5	11
34	Blockade of CD73 using siRNA loaded chitosan lactate nanoparticles functionalized with TAT-hyaluronate enhances doxorubicin mediated cytotoxicity in cancer cells both in vitro and in vivo. <i>International Journal of Biological Macromolecules</i> , 2021, 186, 849-863.	3.6	23
35	Arctigenin, an anti-tumor agent; a cutting-edge topic and up-to-the-minute approach in cancer treatment. <i>European Journal of Pharmacology</i> , 2021, 909, 174419.	1.7	22
36	Adenosine: The common target between cancer immunotherapy and glaucoma in the eye. <i>Life Sciences</i> , 2021, 282, 119796.	2.0	7

#	ARTICLE	IF	CITATIONS
37	Humoral immune mechanisms involved in protective and pathological immunity during COVID-19. <i>Human Immunology</i> , 2021, 82, 733-745.	1.2	47
38	The role of regulatory T cells in the pathogenesis and treatment of prostate cancer. <i>Life Sciences</i> , 2021, 284, 119132.	2.0	26
39	Targeting Wee1 kinase as a therapeutic approach in Hematological Malignancies. <i>DNA Repair</i> , 2021, 107, 103203.	1.3	34
40	Matrix metalloproteinases are involved in the development of neurological complications in patients with Coronavirus disease 2019. <i>International Immunopharmacology</i> , 2021, 100, 108076.	1.7	24
41	The molecular mechanisms and therapeutic potential of EZH2 in breast cancer. <i>Life Sciences</i> , 2021, 286, 120047.	2.0	15
42	Simultaneous blockade of TIGIT and HIF-1 α induces synergistic anti-tumor effect and decreases the growth and development of cancer cells. <i>International Immunopharmacology</i> , 2021, 101, 108288.	1.7	22
43	Clinical, Immunological, and Genetic Features in Patients with Activated PI3K γ Syndrome (APDS): a Systematic Review. <i>Clinical Reviews in Allergy and Immunology</i> , 2020, 59, 323-333.	2.9	79
44	MicroRNAs in breast cancer: Roles, functions, and mechanism of actions. <i>Journal of Cellular Physiology</i> , 2020, 235, 5008-5029.	2.0	68
45	Blockage of immune checkpoint molecules increases T α cell priming potential of dendritic cell vaccine. <i>Immunology</i> , 2020, 159, 75-87.	2.0	67
46	Bronchiectasis in common variable immunodeficiency: A systematic review and meta-analysis. <i>Pediatric Pulmonology</i> , 2020, 55, 292-299.	1.0	32
47	Regulatory T cells in breast cancer as a potent anti-cancer therapeutic target. <i>International Immunopharmacology</i> , 2020, 78, 106087.	1.7	33
48	The effects of cadmium exposure in the induction of inflammation. <i>Immunopharmacology and Immunotoxicology</i> , 2020, 42, 1-8.	1.1	77
49	Stabilization of telomere by the antioxidant property of polyphenols: Anti-aging potential. <i>Life Sciences</i> , 2020, 259, 118341.	2.0	29
50	Codelivery of BV6 and anti-IL6 siRNA by hyaluronate-conjugated PEG-chitosan-lactate nanoparticles inhibits tumor progression. <i>Life Sciences</i> , 2020, 260, 118423.	2.0	22
51	Silencing of IL-6 and STAT3 by siRNA loaded hyaluronate-N,N,N-trimethyl chitosan nanoparticles potently reduces cancer cell progression. <i>International Journal of Biological Macromolecules</i> , 2020, 149, 487-500.	3.6	56
52	Adenosine and adenosine receptors in colorectal cancer. <i>International Immunopharmacology</i> , 2020, 87, 106853.	1.7	24
53	The emerging role of lncRNAs in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2020, 347, 577347.	1.1	22
54	Inhibition of CD73 using folate targeted nanoparticles carrying anti-CD73 siRNA potentiates anticancer efficacy of Dinaciclib. <i>Life Sciences</i> , 2020, 259, 118150.	2.0	22

#	ARTICLE	IF	CITATIONS
55	EP4 receptor as a novel promising therapeutic target in colon cancer. <i>Pathology Research and Practice</i> , 2020, 216, 153247.	1.0	17
56	How microRNAs affect the PD-L1 and its synthetic pathway in cancer. <i>International Immunopharmacology</i> , 2020, 84, 106594.	1.7	19
57	Coinhibition of S1PR1 and GP130 by siRNA-loaded alginate-conjugated trimethyl chitosan nanoparticles robustly blocks development of cancer cells. <i>Journal of Cellular Physiology</i> , 2020, 235, 9702-9717.	2.0	19
58	Clinical, Immunological, and Genetic Features in 49 Patients With ZAP-70 Deficiency: A Systematic Review. <i>Frontiers in Immunology</i> , 2020, 11, 831.	2.2	29
59	Role of microRNAs in epidermal growth factor receptor signaling pathway in cervical cancer. <i>Molecular Biology Reports</i> , 2020, 47, 4553-4568.	1.0	15
60	Concomitant blockade of A2AR and CTLA-4 by siRNA-loaded polyethylene glycol-chitosan-alginate nanoparticles synergistically enhances antitumor T cell responses. <i>Journal of Cellular Physiology</i> , 2020, 235, 10068-10080.	2.0	30
61	Clinical, Immunological, and Genetic Features in Patients with Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-linked (IPEX) and IPEX-like Syndrome. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2747-2760.e7.	2.0	45
62	Silencing adenosine A2a receptor enhances dendritic cell-based cancer immunotherapy. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2020, 29, 102240.	1.7	23
63	Silencing of HIF-1 α /CD73 axis by siRNA-loaded TAT-chitosan-spion nanoparticles robustly blocks cancer cell progression. <i>European Journal of Pharmacology</i> , 2020, 882, 173235.	1.7	48
64	Blockade of CTLA-4 increases anti-tumor response inducing potential of dendritic cell vaccine. <i>Journal of Controlled Release</i> , 2020, 326, 63-74.	4.8	56
65	Silencing of p68 and STAT3 synergistically diminishes cancer progression. <i>Life Sciences</i> , 2020, 249, 117499.	2.0	31
66	The roles of ERAP1 and ERAP2 in autoimmunity and cancer immunity: New insights and perspective. <i>Molecular Immunology</i> , 2020, 121, 7-19.	1.0	37
67	Endoplasmic reticulum aminopeptidase 2 gene single nucleotide polymorphisms in association with susceptibility to ankylosing spondylitis in an Iranian population. <i>Immunology Letters</i> , 2020, 223, 97-105.	1.1	4
68	PD-L1/PD-1 axis as a potent therapeutic target in breast cancer. <i>Life Sciences</i> , 2020, 247, 117437.	2.0	33
69	Preparation and in-vitro evaluation of pH-responsive cationic cyclodextrin coated magnetic nanoparticles for delivery of methotrexate to the Saos-2 bone cancer cells. <i>Journal of Drug Delivery Science and Technology</i> , 2020, 57, 101584.	1.4	30
70	Cancer associated fibroblasts as novel promising therapeutic targets in breast cancer. <i>Pathology Research and Practice</i> , 2020, 216, 152915.	1.0	39
71	Critical roles of long noncoding RNAs in breast cancer. <i>Journal of Cellular Physiology</i> , 2020, 235, 5059-5071.	2.0	38
72	Immunological and oxidative stress biomarkers in Ankylosing Spondylitis patients with or without metabolic syndrome. <i>Cytokine</i> , 2020, 128, 155002.	1.4	33

#	ARTICLE	IF	CITATIONS
73	Clinical application of immune checkpoints in targeted immunotherapy of prostate cancer. <i>Cellular and Molecular Life Sciences</i> , 2020, 77, 3693-3710.	2.4	48
74	Codelivery of STAT3 siRNA and BV6 by carboxymethyl dextran trimethyl chitosan nanoparticles suppresses cancer cell progression. <i>International Journal of Pharmaceutics</i> , 2020, 581, 119236.	2.6	50
75	Nanomedicine for improvement of dendritic cell-based cancer immunotherapy. <i>International Immunopharmacology</i> , 2020, 83, 106446.	1.7	30
76	Tumor associated macrophages in the molecular pathogenesis of ovarian cancer. <i>International Immunopharmacology</i> , 2020, 84, 106471.	1.7	18
77	CDK1 in Breast Cancer: Implications for Theranostic Potential. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2020, 20, 758-767.	0.9	57
78	Diagnostic Approach to the Patients with Suspected Primary Immunodeficiency. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2020, 20, 157-171.	0.6	15
79	Optimized Dose of Dendritic Cell-based Vaccination in Experimental Model of Tumor Using Artificial Neural Network. <i>Iranian Journal of Allergy, Asthma and Immunology</i> , 2020, 19, 172-182.	0.3	1
80	Conjugated CAR T cell one step beyond conventional CAR T cell for a promising cancer immunotherapy. <i>Cellular Immunology</i> , 2019, 345, 103963.	1.4	9
81	Potential of CD73 as a target for cancer immunotherapy. <i>Immunotherapy</i> , 2019, 11, 1353-1355.	1.0	10
82	Hypoxia inducible factors in the tumor microenvironment as therapeutic targets of cancer stem cells. <i>Life Sciences</i> , 2019, 237, 116952.	2.0	69
83	Malignancy in common variable immunodeficiency: a systematic review and meta-analysis. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 1105-1113.	1.3	47
84	The role of IL-10-producing B cells in repeated implantation failure patients with cellular immune abnormalities. <i>Immunology Letters</i> , 2019, 214, 16-22.	1.1	12
85	E2 ubiquitin-conjugating enzymes in cancer: Implications for immunotherapeutic interventions. <i>Clinica Chimica Acta</i> , 2019, 498, 126-134.	0.5	33
86	S1PR1 as a Novel Promising Therapeutic Target in Cancer Therapy. <i>Molecular Diagnosis and Therapy</i> , 2019, 23, 467-487.	1.6	37
87	Overexpression of tensin homolog deleted on chromosome ten (PTEN) by ciglitazone sensitizes doxorubicin-resistant leukemia cancer cells to treatment. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 15719-15729.	1.2	6
88	Prostaglandin E2 as a potent therapeutic target for treatment of colon cancer. <i>Prostaglandins and Other Lipid Mediators</i> , 2019, 144, 106338.	1.0	79
89	Cytokine profile, Treg/Th17 cell frequency changes during different posttransplantational time points in patients undergoing renal transplantation. <i>Journal of Cellular Physiology</i> , 2019, 234, 20935-20943.	2.0	5
90	Cyclosporine A improves pregnancy outcomes in women with recurrent pregnancy loss and elevated Th1/Th2 ratio. <i>Journal of Cellular Physiology</i> , 2019, 234, 19039-19047.	2.0	36

#	ARTICLE	IF	CITATIONS
91	Downregulation of A2AR by siRNA loaded PEG-chitosan-lactate nanoparticles restores the T cell mediated anti-tumor responses through blockage of PKA/CREB signaling pathway. <i>International Journal of Biological Macromolecules</i> , 2019, 133, 436-445.	3.6	58
92	CD73 as a potential opportunity for cancer immunotherapy. <i>Expert Opinion on Therapeutic Targets</i> , 2019, 23, 127-142.	1.5	102
93	The role of DEAD-box RNA helicase p68 (DDX5) in the development and treatment of breast cancer. <i>Journal of Cellular Physiology</i> , 2019, 234, 5478-5487.	2.0	41
94	T cell Subsets in Peripheral Blood of Women with Recurrent Implantation Failure. <i>Journal of Reproductive Immunology</i> , 2019, 131, 21-29.	0.8	48
95	Interleukin-33 gene expression and rs1342326 polymorphism in Behçet's disease. <i>Immunology Letters</i> , 2019, 212, 120-124.	1.1	14
96	The profile of IL-4, IL-5, IL-10 and GATA3 in patients with LRBA deficiency and CVID with no known monogenic disease: Association with disease severity. <i>Allergologia Et Immunopathologia</i> , 2019, 47, 172-178.	1.0	12
97	Intravenous immunoglobulin G treatment increases live birth rate in women with recurrent miscarriage and modulates regulatory and exhausted regulatory T cells frequency and function. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 5424-5434.	1.2	19
98	Dimethyl fumarate: Regulatory effects on the immune system in the treatment of multiple sclerosis. <i>Journal of Cellular Physiology</i> , 2019, 234, 9943-9955.	2.0	29
99	Smac mimetics as novel promising modulators of apoptosis in the treatment of breast cancer. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 9300-9314.	1.2	23
100	A role for Th1-like Th17 cells in the pathogenesis of inflammatory and autoimmune disorders. <i>Molecular Immunology</i> , 2019, 105, 107-115.	1.0	122
101	Investigation of follicular helper T cells, as a novel player, in preeclampsia. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 3845-3852.	1.2	18
102	The imbalance of Th17/Treg axis involved in the pathogenesis of preeclampsia. <i>Journal of Cellular Physiology</i> , 2019, 234, 5106-5116.	2.0	91
103	The importance of miRNAs and epigenetics in acute lymphoblastic leukemia prognosis. <i>Journal of Cellular Physiology</i> , 2019, 234, 3216-3230.	2.0	24
104	A review on medicinal plant extracts and their active ingredients against methicillin-resistant and methicillin-sensitive <i>Staphylococcus aureus</i> . <i>Journal of HerbMed Pharmacology</i> , 2019, 8, 173-184.	0.4	12
105	Apoptotic Effects of Mucin1 Aptamer-Conjugated Nanoparticles Containing Docetaxel and c-Met siRNA on SKBR3 Human Metastatic Breast Cancer Cells. <i>Jundishapur Journal of Natural Pharmaceutical Products</i> , 2019, 14, .	0.3	1
106	Anti-Mucin1 Aptamer-Conjugated Chitosan Nanoparticles for Targeted Co-Delivery of Docetaxel and IGF-1R siRNA to SKBR3 Metastatic Breast Cancer Cells. <i>Iranian Biomedical Journal</i> , 2019, 23, 21-33.	0.4	9
107	Rheumatologic complications in a cohort of 227 patients with common variable immunodeficiency. <i>Scandinavian Journal of Immunology</i> , 2018, 87, e12663.	1.3	27
108	Peripheral Th17/Treg imbalance in elderly patients with ischemic stroke. <i>Neurological Sciences</i> , 2018, 39, 647-654.	0.9	70

#	ARTICLE	IF	CITATIONS
109	Anti-inflammatory and anti-tumor effects of α -L-galacturonic acid (G2013) on cancer-related inflammation in a murine breast cancer model. <i>Biomedicine and Pharmacotherapy</i> , 2018, 98, 793-800.	2.5	43
110	Chitosan (CMD)-mediated co-delivery of SN38 and Snail-specific siRNA as a useful anticancer approach against prostate cancer. <i>Pharmacological Reports</i> , 2018, 70, 418-425.	1.5	31
111	TNF-related apoptosis-inducing ligand (TRAIL) as the potential therapeutic target in hematological malignancies. <i>Biomedicine and Pharmacotherapy</i> , 2018, 98, 566-576.	2.5	34
112	Molecular analysis of interleukin-10 gene polymorphisms in patients with Behçet's disease. <i>Immunology Letters</i> , 2018, 194, 56-61.	1.1	16
113	Current approaches for the treatment of premature ovarian failure with stem cell therapy. <i>Biomedicine and Pharmacotherapy</i> , 2018, 102, 254-262.	2.5	89
114	Adenosine and adenosine receptors in the immunopathogenesis and treatment of cancer. <i>Journal of Cellular Physiology</i> , 2018, 233, 2032-2057.	2.0	116
115	Co-delivery of insulin-like growth factor 1 receptor specific siRNA and doxorubicin using chitosan-based nanoparticles enhanced anticancer efficacy in A549 lung cancer cell line. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2018, 46, 293-302.	1.9	25
116	The role of innate lymphoid cells in health and disease. <i>Journal of Cellular Physiology</i> , 2018, 233, 4512-4529.	2.0	37
117	Inhibition of tumor growth by mouse ROR1 specific antibody in a syngeneic mouse tumor model. <i>Immunology Letters</i> , 2018, 193, 35-41.	1.1	17
118	The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer. <i>Biomedicine and Pharmacotherapy</i> , 2018, 108, 1415-1424.	2.5	201
119	Polymorphism of Foxp3 gene affects the frequency of regulatory T cells and disease activity in patients with rheumatoid arthritis in Iranian population. <i>Immunology Letters</i> , 2018, 204, 16-22.	1.1	22
120	Anti-angiogenic effects of CD73-specific siRNA-loaded nanoparticles in breast cancer-bearing mice. <i>Journal of Cellular Physiology</i> , 2018, 233, 7165-7177.	2.0	56
121	Targeted Co-Delivery of Docetaxel and cMET siRNA for Treatment of Mucin1 Overexpressing Breast Cancer Cells. <i>Advanced Pharmaceutical Bulletin</i> , 2018, 8, 383-393.	0.6	22
122	The impact of the codelivery of drug-siRNA by trimethyl chitosan nanoparticles on the efficacy of chemotherapy for metastatic breast cancer cell line (MDA-MB-231). <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2017, 45, 889-896.	1.9	34
123	Immune regulatory network in successful pregnancy and reproductive failures. <i>Biomedicine and Pharmacotherapy</i> , 2017, 88, 61-73.	2.5	101
124	Isolation and characterization of anti ROR1 single chain fragment variable antibodies using phage display technique. <i>Human Antibodies</i> , 2017, 25, 57-63.	0.6	10
125	Targeting of crosstalk between tumor and tumor microenvironment by α -D-mannuronic acid (M2000) in murine breast cancer model. <i>Cancer Medicine</i> , 2017, 6, 640-650.	1.3	37
126	The c-Met receptor: Implication for targeted therapies in colorectal cancer. <i>Tumor Biology</i> , 2017, 39, 101042831769911.	0.8	42

#	ARTICLE	IF	CITATIONS
127	Chitosan nanoparticles as a dual drug/siRNA delivery system for treatment of colorectal cancer. <i>Immunology Letters</i> , 2017, 181, 79-86.	1.1	87
128	Effect of Intravenous immunoglobulin on Th1 and Th2 lymphocytes and improvement of pregnancy outcome in recurrent pregnancy loss (RPL). <i>Biomedicine and Pharmacotherapy</i> , 2017, 92, 1095-1102.	2.5	47
129	Increased efficacy of a dendritic cell-based therapeutic cancer vaccine with adenosine receptor antagonist and CD73 inhibitor. <i>Tumor Biology</i> , 2017, 39, 101042831769502.	0.8	52
130	Multiple sclerosis: Therapeutic applications of advancing drug delivery systems. <i>Biomedicine and Pharmacotherapy</i> , 2017, 86, 343-353.	2.5	56
131	CD73 specific siRNA loaded chitosan lactate nanoparticles potentiate the antitumor effect of a dendritic cell vaccine in 4T1 breast cancer bearing mice. <i>Journal of Controlled Release</i> , 2017, 246, 46-59.	4.8	142
132	Intravenous immunoglobulin (IVIg) treatment modulates peripheral blood Th17 and regulatory T cells in recurrent miscarriage patients: Non randomized, open-label clinical trial. <i>Immunology Letters</i> , 2017, 192, 12-19.	1.1	32
133	Nanoparticles and targeted drug delivery in cancer therapy. <i>Immunology Letters</i> , 2017, 190, 64-83.	1.1	374
134	The paradox of Th17 cell functions in tumor immunity. <i>Cellular Immunology</i> , 2017, 322, 15-25.	1.4	148
135	The use of nanoparticles as a promising therapeutic approach in cancer immunotherapy. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2016, 44, 1-11.	1.9	56
136	Mesenchymal Stem Cells in the Treatment of Amyotrophic Lateral Sclerosis. <i>Current Stem Cell Research and Therapy</i> , 2016, 11, 41-50.	0.6	21
137	Evaluation of EBV transformation of human memory B-cells isolated by FACS and MACS techniques. <i>Journal of Immunotoxicology</i> , 2016, 13, 490-497.	0.9	6
138	Mechanisms of tumor cell resistance to the current targeted-therapy agents. <i>Tumor Biology</i> , 2016, 37, 10021-10039.	0.8	60
139	Inhibition of HIF-1 α enhances anti-tumor effects of dendritic cell-based vaccination in a mouse model of breast cancer. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 1159-1167.	2.0	74
140	Application of nanoparticle technology in the treatment of Systemic lupus erythematosus. <i>Biomedicine and Pharmacotherapy</i> , 2016, 83, 1154-1163.	2.5	22
141	The insulin-like growth factor-I receptor (IGF-IR) in breast cancer: biology and treatment strategies. <i>Tumor Biology</i> , 2016, 37, 11711-11721.	0.8	35
142	Application of nanomedicine for crossing the blood-brain barrier: Theranostic opportunities in multiple sclerosis. <i>Journal of Immunotoxicology</i> , 2016, 13, 603-619.	0.9	38
143	Effects of HMGA2 siRNA and doxorubicin dual delivery by chitosan nanoparticles on cytotoxicity and gene expression of HT-29 colorectal cancer cell line. <i>Journal of Pharmacy and Pharmacology</i> , 2016, 68, 1119-1130.	1.2	60
144	Novel immunotherapeutic approaches for treatment of infertility. <i>Biomedicine and Pharmacotherapy</i> , 2016, 84, 1449-1459.	2.5	28

#	ARTICLE	IF	CITATIONS
145	Comparative human and mouse antibody responses against tetanus toxin at clonal level. <i>Journal of Immunotoxicology</i> , 2016, 13, 243-248.	0.9	7
146	The role of oncomirs in the pathogenesis and treatment of breast cancer. <i>Biomedicine and Pharmacotherapy</i> , 2016, 78, 129-139.	2.5	66
147	Utilization of nanoparticle technology in rheumatoid arthritis treatment. <i>Biomedicine and Pharmacotherapy</i> , 2016, 80, 30-41.	2.5	132
148	The role of adenosine and adenosine receptors in the immunopathogenesis of multiple sclerosis. <i>Inflammation Research</i> , 2016, 65, 511-520.	1.6	41
149	Downregulation of CD73 in 4T1 breast cancer cells through siRNA-loaded chitosan-lactate nanoparticles. <i>Tumor Biology</i> , 2016, 37, 8403-8412.	0.8	61
150	The immunobiology of myeloid-derived suppressor cells in cancer. <i>Tumor Biology</i> , 2016, 37, 1387-1406.	0.8	83
151	IL-21 and IL-21 receptor in the immunopathogenesis of multiple sclerosis. <i>Journal of Immunotoxicology</i> , 2016, 13, 274-285.	0.9	31
152	Ibrutinib-A double-edge sword in cancer and autoimmune disorders. <i>Journal of Drug Targeting</i> , 2016, 24, 373-385.	2.1	21
153	CAR-modified T-cell therapy for cancer: an updated review. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2016, 44, 1339-1349.	1.9	45
154	Recombinant <i>Leishmania major</i> lipophosphoglycan 3 activates human T-lymphocytes via TLR2-independent pathway. <i>Journal of Immunotoxicology</i> , 2016, 13, 263-269.	0.9	4
155	Immunology of Chronic Obstructive Pulmonary Disease and Sulfur Mustard Induced Airway Injuries: Implications for Immunotherapeutic Interventions. <i>Current Pharmaceutical Design</i> , 2016, 22, 2975-2996.	0.9	14
156	Synergistic induction of apoptosis in B-cell chronic lymphocytic leukemia cells after treatment with all-trans retinoic acid in combination with interleukin-21 and rituximab. <i>Journal of Cancer Research and Therapeutics</i> , 2016, 12, 1278.	0.3	4
157	Design and construction of immune phage antibody library against Tetanus neurotoxin: Production of single chain antibody fragments. <i>Human Antibodies</i> , 2015, 23, 73-79.	0.6	5
158	The immunomodulatory effects of fish-oil supplementation in elite paddlers: A pilot randomized double blind placebo-controlled trial. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2015, 99, 35-40.	1.0	9
159	Analysis of human B cell response to recombinant <i>Leishmania</i> LPG3. <i>Asian Pacific Journal of Tropical Medicine</i> , 2015, 8, 624-629.	0.4	2
160	All-Trans-Retinoic Acid Differentially Regulates Proliferation of Normal and Leukemic B Cells From Different Subsets of Chronic Lymphocytic Leukemia. <i>Nutrition and Cancer</i> , 2015, 67, 285-291.	0.9	7
161	Immunomodulatory characteristics of mesenchymal stem cells and their role in the treatment of Multiple Sclerosis. <i>Cellular Immunology</i> , 2015, 293, 113-121.	1.4	93
162	Folate-conjugated nanoparticles as a potent therapeutic approach in targeted cancer therapy. <i>Tumor Biology</i> , 2015, 36, 5727-5742.	0.8	96

#	ARTICLE	IF	CITATIONS
163	The skewed balance between Tregs and Th17 in chronic lymphocytic leukemia. <i>Future Oncology</i> , 2015, 11, 1567-1582.	1.1	25
164	Immunotherapeutic approaches for cancer therapy: An updated review. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2015, 44, 1-11.	1.9	41
165	MicroRNA-induced drug resistance in gastric cancer. <i>Biomedicine and Pharmacotherapy</i> , 2015, 74, 191-199.	2.5	49
166	Myeloid-derived suppressor cells in B cell malignancies. <i>Tumor Biology</i> , 2015, 36, 7339-7353.	0.8	53
167	Molecular Cloning and Expression of Novel Fibroblast Growth Factor-2 Conjugated with Immunodominant Domains of Pseudomonas exotoxin. <i>Biomedical and Pharmacology Journal</i> , 2015, 8, 1195-1200.	0.2	0
168	The role of leukotrienes in immunopathogenesis of rheumatoid arthritis. <i>Modern Rheumatology</i> , 2014, 24, 225-235.	0.9	31
169	The Significance of Matrix Metalloproteinases in the Immunopathogenesis and Treatment of Multiple Sclerosis	0.3	55
170	Regulatory T cells in chronic lymphocytic leukemia: implication for immunotherapeutic interventions. <i>Tumor Biology</i> , 2013, 34, 2031-2039.	0.8	48
171	The role of natural killer T cells in B cell malignancies. <i>Tumor Biology</i> , 2013, 34, 1349-1360.	0.8	40
172	Th17 Cells in Immunopathogenesis and treatment of rheumatoid arthritis. <i>International Journal of Rheumatic Diseases</i> , 2013, 16, 243-253.	0.9	93
173	Differential regulation of B-cell proliferation by IL21 in different subsets of chronic lymphocytic leukemia. <i>Cytokine</i> , 2013, 62, 439-445.	1.4	20
174	The role of leukotrienes in immunopathogenesis of rheumatoid arthritis. <i>Modern Rheumatology</i> , 2013, 1.	0.9	9
175	Downregulation of IL-17-producing T cells is associated with regulatory T cell expansion and disease progression in chronic lymphocytic leukemia. <i>Tumor Biology</i> , 2013, 34, 929-940.	0.8	60
176	Increased Frequency of CD8 ⁺ and CD4 ⁺ Regulatory T Cells in Chronic Lymphocytic Leukemia: Association with Disease Progression. <i>Cancer Investigation</i> , 2013, 31, 121-131.	0.6	49
177	The Role of Different Subsets of Regulatory T Cells in Immunopathogenesis of Rheumatoid Arthritis. <i>Arthritis</i> , 2012, 2012, 1-16.	2.0	78
178	The Role of Natural Killer Cells in Alzheimer's Disease. <i>Scandinavian Journal of Immunology</i> , 2012, 76, 451-456.	1.3	31
179	The deviated balance between regulatory T cell and Th17 in autoimmunity. <i>Immunopharmacology and Immunotoxicology</i> , 2012, 34, 727-739.	1.1	44
180	Reduced frequency of NKT-like cells in patients with progressive chronic lymphocytic leukemia. <i>Medical Oncology</i> , 2012, 29, 3561-3569.	1.2	54

#	ARTICLE	IF	CITATIONS
181	Regulatory T-cell as orchestra leader in immunosuppression process of multiple sclerosis. Immunopharmacology and Immunotoxicology, 2011, 33, 545-567.	1.1	44
182	Therapeutic Approach to Multiple Sclerosis by Novel Oral Drugs. Recent Patents on Inflammation and Allergy Drug Discovery, 2011, 5, 66-80.	3.9	12
183	Th17 Cell, the New Player of Neuroinflammatory Process in Multiple Sclerosis. Scandinavian Journal of Immunology, 2011, 74, 1-13.	1.3	324
184	Prostaglandins in pathogenesis and treatment of multiple sclerosis. Immunopharmacology and Immunotoxicology, 2010, 32, 543-554.	1.1	37
185	Immunopharmacological role of the Leukotriene Receptor Antagonists and inhibitors of leukotrienes generating enzymes in Multiple Sclerosis. Immunopharmacology and Immunotoxicology, 2010, 32, 219-227.	1.1	21
186	Histamine and histamine receptors in pathogenesis and treatment of multiple sclerosis. Neuropharmacology, 2010, 59, 180-189.	2.0	81
187	The role of <scp>SF3B1</scp> and <scp>NOTCH1</scp> in the pathogenesis of leukemia. IUBMB Life, 0, , .	1.5	1